selected scholarly activity
-
academic article
- Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis. Bone Marrow Transplantation. 1-13. 2023
- High transferrin saturation predicts inferior clinical outcomes in patients with myelodysplastic syndromes. Haematologica. 108:532-542. 2023
- The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia and Lymphoma. ahead-of-print:1-11. 2023
-
Perioperative management of myeloproliferative neoplasms: A
pan‐Canadian physician survey and international expert opinion. American Journal of Hematology. 97:E466-E469. 2022 - Real-World Treatment Patterns and Clinical Outcomes in Canadian Patients with AML Unfit for First-Line Intensive Chemotherapy. Current Oncology. 29:6794-6806. 2022
- The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. Annals of Hematology. 101:1023-1030. 2022
- Efficacy and specificity of inhibitors of BCL-2 family protein interactions assessed by affinity measurements in live cells. Science advances. 8:eabm7375. 2022
- BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. British Journal of Haematology. 196:136-145. 2022
- Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology. 100:1917-1918. 2021
- Patient‐reported fatigue refines prognosis in higher‐risk myelodysplastic syndromes (MDS): a MDS‐CAN study. British Journal of Haematology. 194:319-324. 2021
- Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology. 100:1181-1194. 2021
- Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. British Journal of Haematology. 193:779-791. 2021
- Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario. Current Oncology. 28:1376-1387. 2021
- Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients. Cell Reports. 34:108845-108845. 2021
- Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. Cell Reports Medicine. 2:100202-100202. 2021
- Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma. 61:3287-3305. 2020
- Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia. 34:3434-3438. 2020
- Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology. 13:92. 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine. 383:617-629. 2020
- Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group. JCO Oncology Practice. 16:351-359. 2020
- An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia. 34:1394-1406. 2020
- Hand Mirror Cells and Hypercalcemia: A Rare Presentation of Pediatric Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology. 42:e181-e184. 2020
- Allosteric Regulation of BH3 Proteins in Bcl-xL Complexes Enables Switch-like Activation of Bax. Molecular Cell. 77:901-912.e9. 2020
- The carboxyl-terminal sequence of bim enables bax activation and killing of unprimed cells. eLife. 9:e44525. 2020
- The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia. Leukemia Research. 88:106285-106285. 2020
- Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Leukemia and Lymphoma. 60:3493-3502. 2019
- Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2. eLife. 8:e37689. 2019
- How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. European Journal of Haematology. 102:36-52. 2019
- Unleashing Blocked Apoptosis in Cancer Cells: New MCL1 Inhibitors Find Their Groove. Cancer Discovery. 8:1511-1514. 2018
- Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS. Leukemia Research. 74:21-41. 2018
- Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell. 34:483-498.e5. 2018
- Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Reports. 19:e45235. 2018
- A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances. 2:1935-1945. 2018
- Cyclic thrombocytopenia with statistically significant neutrophil oscillations. Clinical Case Reports. 6:1347-1352. 2018
- A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. Annals of Hematology. 96:2025-2029. 2017
- Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nature Cell Biology. 19:1336-1347. 2017
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia. 31:2529-2531. 2017
- ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems. American Journal of Hematology. 92:1037-1046. 2017
- Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. British Journal of Haematology. 179:83-97. 2017
- Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology. 24:833-844.e9. 2017
- A Small-Molecule Inhibitor of Bax and Bak Oligomerization Prevents Genotoxic Cell Death and Promotes Neuroprotection. Cell Chemical Biology. 24:493-506.e5. 2017
- Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.. American Journal of Blood Research. 7:30-40. 2017
- Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells. Oncotarget. 7:72608-72621. 2016
- Laboratory Investigation of Myeloproliferative Neoplasms (MPNs). American Journal of Clinical Pathology. 146:408-422. 2016
- High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. 128:934-947. 2016
- Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. British Journal of Haematology. 174:88-101. 2016
- Small molecules reveal an alternative mechanism of Bax activation. Biochemical Journal. 473:1073-1083. 2016
- Gender andBCR-ABLtranscript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. European Journal of Haematology. 96:360-366. 2016
- Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. Clinical Lymphoma, Myeloma and Leukemia. 15:715-727. 2015
- Effect of Lactobacillus casei Shirota supplementation on trimethylamine-N-oxide levels in patients with metabolic syndrome: An open-label, randomized study. Atherosclerosis. 242:141-144. 2015
- Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells—Mitochondrial Outer Membrane Permeabilization and Beyond. Clinical Cancer Research. 21:2671-2676. 2015
- Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. Stem Cells. 33:1839-1849. 2015
- Distinct lipid effects on tBid and Bim activation of membrane permeabilization by pro-apoptotic Bax. Biochemical Journal. 467:495-505. 2015
- Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 29:526-534. 2015
- Increased eculizumab requirements during pregnancy in a patient with paroxysmal nocturnal hemoglobinuria: case report and review of the literature. Clinical Case Reports. 3:88-91. 2015
- Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O6-methylguanine DNA methyltransferase expression. British Journal of Haematology. 167:664-670. 2014
- A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults. Current Oncology. 21:234-250. 2014
- Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. Journal of Experimental Medicine. 211:1925-1935. 2014
- Regulating cell death at, on, and in membranes. Biochimica et Biophysica Acta - Molecular Cell Research. 1843:2100-2113. 2014
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 124:729-736. 2014
- The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature Nature: New biology. 511:90-93. 2014
- Multiple partners can kiss-and-run: Bax transfers between multiple membranes and permeabilizes those primed by tBid. Cell Death and Disease. 5:e1277-e1277. 2014
- The Proapoptotic Protein tBid Forms Both Superficially Bound and Membrane-Inserted Oligomers. Biophysical Journal. 106:2085-2095. 2014
- Evidence-Based Guidelines for the Use of Tyrosine Kinase Inhibitors in Adults with Philadelphia Chromosome–Positive or Bcr-Abl–Positive Acute Lymphoblastic Leukemia: A Canadian Consensus. Current Oncology. 21:265-309. 2014
- Optimizing Outcomes with Azacitidine: Recommendations from Canadian Centres of Excellence. Current Oncology. 21:44-50. 2014
- Examining the Molecular Mechanism of Bcl-2 Family Proteins at Membranes by Fluorescence Spectroscopy. Methods in Enzymology. 544:1-23. 2014
- tBid Undergoes Multiple Conformational Changes at the Membrane Required for Bax Activation. Journal of Biological Chemistry. 288:22111-22127. 2013
- A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leukemia and Lymphoma. 54:760-766. 2013
- Mechanisms of Action of Bcl-2 Family Proteins. Cold Spring Harbor perspectives in biology. 5:a008714-a008714. 2013
- Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus.. American Journal of Blood Research. 3:141-164. 2013
- Shedding Light on Apoptosis at Subcellular Membranes. Cell. 151:1179-1184. 2012
- A Review of Pneumatosis Intestinalis in the Setting of Systemic Cancer Treatments, Including Tyrosine Kinase Inhibitors. Canadian Association of Radiologists Journal. 63:312-317. 2012
- GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo. Cancer Research. 72:5374-5385. 2012
- Interactions of pro-apoptotic BH3 proteins with anti-apoptotic Bcl-2 family proteins measured in live MCF-7 cells using FLIM FRET. Cell Cycle. 11:3536-3542. 2012
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. Cell. 149:1284-1297. 2012
- Multiple post-translational modifications regulate E-cadherin transport during apoptosis. Journal of Cell Science. 125:2615-2625. 2012
- Differences in the Mechanisms of Proapoptotic BH3 Proteins Binding to Bcl-XL and Bcl-2 Quantified in Live MCF-7 Cells. Molecular Cell. 45:754-763. 2012
- Impact of temperature on cell death in a cell-culture model of hepatocellular carcinoma.. Anticancer Research. 32:915-921. 2012
- Interaction of the full-length Bax protein with biomimetic mitochondrial liposomes: A small-angle neutron scattering and fluorescence study. Biochimica et Biophysica Acta - Biomembranes Biochimica et Biophysica Acta - Reviews on Biomembranes. 1818:384-401. 2012
- Cell to cell interactions influence sensitivity of liver cell lines during hyperthermia.. Anticancer Research. 31:3713-3717. 2011
- cml Biology for the Clinician in 2011: Six Impossible Things to Believe before Breakfast on the Way to Cure. Current Oncology. 18:185-190. 2011
- Identification of T-lymphocytic leukemia–initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood. 117:7112-7120. 2011
- Effect of hyperthermia on liver cell lines: important findings for thermal therapy in hepatocellular carcinoma.. Anticancer Research. 31:1583-1588. 2011
- BH3-only proteins: Orchestrators of apoptosis. Biochimica et Biophysica Acta - Molecular Cell Research. 1813:508-520. 2011
- Closing in on the link between apoptosis and autophagy. F1000 Biology Reports. 2:88. 2010
- Apoptosis: embedded in membranes. Current Opinion in Cell Biology. 22:845-851. 2010
- Mixed Variant Multicentric Castleman Disease Treated With Rituximab: Case Report. Journal of Pediatric Hematology/Oncology. 32:622-622. 2010
- Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene. 29:5221-5230. 2010
- The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood. 116:1433-1442. 2010
- Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Reviews in Molecular Medicine. 12:e28. 2010
- Proteins Required for Centrosome Clustering in Cancer Cells. Science Translational Medicine. 2:33ra38. 2010
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leukemia and Lymphoma. 51:252-260. 2010
- BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38− cells, through activation of protein kinase Cβ. Blood. 114:4186-4196. 2009
- A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation. 44:317-320. 2009
- Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114:257-260. 2009
- A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over. Leukemia. 23:631-634. 2009
- Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 112:4639-4645. 2008
- Membrane Binding by tBid Initiates an Ordered Series of Events Culminating in Membrane Permeabilization by Bax. Cell. 135:1074-1084. 2008
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology. 143:355-360. 2008
- Iron overload in myelodysplastic syndromes: A Canadian consensus guideline. Leukemia Research. 32:1338-1353. 2008
- O-GlcNAc-glycosylation of β-catenin regulates its nuclear localization and transcriptional activity. Experimental Cell Research. 314:2774-2787. 2008
- Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax. PLoS Biology. 6:e147-e147. 2008
- Stem cell transplantation in advanced cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology. 58:645-649. 2008
- Acute pancreatitis preceding thrombotic thrombocytopenic Purpura. Haematologica. 92:e94-e95. 2007
- Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura. Vox Sanguinis. 93:173-175. 2007
- Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes. Apoptosis : an international journal on programmed cell death. 12:897-911. 2007
- Circumvention of Fluorophore Photobleaching in Fluorescence Fluctuation Experiments: a Beam Scanning Approach. ChemPhysChem. 8:834-848. 2007
- Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer. 6:213. 2006
- Bcl-2 changes conformation to inhibit Bax oligomerization. EMBO Journal. 25:2287-2296. 2006
- Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate. Leukemia and Lymphoma. 47:297-306. 2006
- Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO Journal. 24:2096-2103. 2005
- During Apoptosis Bcl-2 Changes Membrane Topology at Both the Endoplasmic Reticulum and Mitochondria. Molecular Cell. 14:523-529. 2004
- There is more to life and death than mitochondria: Bcl-2 proteins at the endoplasmic reticulum. Biochimica et Biophysica Acta - Molecular Cell Research. 1644:115-123. 2004
- Interaction with a Membrane Surface Triggers a Reversible Conformational Change in Bax Normally Associated with Induction of Apoptosis. Journal of Biological Chemistry. 278:48935-48941. 2003
- Prolonged complete remission in two cases of acute promyelocytic leukaemia treated with atra alone. British Journal of Haematology. 117:768-768. 2002
- Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology. 20:205-213. 2002
- Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. Journal of Clinical Oncology. 20:205-213. 2002
- Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. EMBO Journal. 20:5999-6007. 2001
- Myc Potentiates Apoptosis by Stimulating Bax Activity at the Mitochondria. Molecular and Cellular Biology. 21:4725-4736. 2001
- CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. American Journal of Hematology. 67:34-41. 2001
- Endoplasmic reticulum localized Bcl-2 prevents apoptosis when redistribution of cytochrome c is a late event. Oncogene. 20:1939-1952. 2001
- Assessing pore formation by BCL-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment. Blood. 96. 2000
- The hemochromatosis gene. Clinical and Investigative Medicine. 23:334-338. 2000
- The hemochromatosis gene.. Clinical and Investigative Medicine. 23:382-386. 2000
- Mitochondrio‐nuclear translocation of AIF in apoptosis and necrosis. FASEB Journal. 14:729-739. 2000
- Bcl-2 and Bax regulate the channel activity of the mitochondrial adenine nucleotide translocator. Oncogene. 19:329-336. 2000
- Identification of the Endoplasmic Reticulum Targeting Signal in Vesicle-associated Membrane Proteins. Journal of Biological Chemistry. 274:36876-36882. 1999
- Radiotherapy to control CNS lymphomatoid granulomatosis: A case report and review of the literature. American Journal of Hematology. 62:239-241. 1999
- Regulation of Acidification and Apoptosis by SHP-1 and Bcl-2. Journal of Biological Chemistry. 274:29549-29557. 1999
- Bcl-2 targeted to the endoplasmic reticulum can inhibit apoptosis induced by Myc but not etoposide in Rat-1 fibroblasts. Oncogene. 18:3520-3528. 1999
- Inhibition of p53 Transcriptional Activity by Bcl-2 Requires Its Membrane-anchoring Domain. Journal of Biological Chemistry. 274:6469-6475. 1999
- Patients with type 2 diabetes have a high frequency of the C282Y mutation of the hemochromatosis gene.. Clinical and Investigative Medicine. 21:251-257. 1998
- PML/RARα APL with undifferentiated morphology and stem cell immunophenotype. Leukemia. 12:1492-1493. 1998
- At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes. Oncogene. 17:565-576. 1998
- Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants. American Journal of Hematology. 56:131-142. 1997
- Evidence for Multiple Mechanisms for Membrane Binding and Integration via Carboxyl-Terminal Insertion Sequences. Biochemistry. 36:8873-8882. 1997
- Bax Homodimerization Is Not Required for Bax to Accelerate Chemotherapy-induced Cell Death. Journal of Biological Chemistry. 271:32073-32077. 1996
- Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types.. EMBO Journal. 15:4130-4141. 1996
- The role of the bone marrow in allergy and asthma. Allergy: European Journal of Allergy and Clinical Immunology. 51:141-148. 1996
- Telomeres and Telomerase in Normal and Malignant Haematologic Cells. Leukemia and Lymphoma. 24:1-9. 1996
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 13:2386-2393. 1995
- Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 85:2315-2320. 1995
- Basophil and eosinophil differentiation in allergic reactions. Journal of Allergy and Clinical Immunology. 94:1135-1141. 1994
- Targeting of passenger protein domains to multiple intracellular membranes. Biochemical Journal. 300:191-199. 1994
- Assembly of Bcl-2 into microsomal and outer mitochondrial membranes. Journal of Biological Chemistry. 269:9842-9849. 1994
- Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: recovery complicated by initial pancytopenia and late dermatomyositis.. Bone Marrow Transplantation. 12:405-407. 1993
- B-cell lymphoma of recipient origin 9 years after allogeneic bone marrow transplantation for T-cell acute lymphoblastic leukaemia. British Journal of Haematology. 85:99-102. 1993
- Nucleotide sequences of an antiidiotypic antibody from a transplant recipient. Immunogenetics. 38:242. 1993
- Rearrangement of TCR gamma chain gene involving JP1 suggests early thymocyte origin of peripheral T-cell lymphoma. European Journal of Haematology. 42:368-374. 1989
- Abnormalities in T-cell associated rearrangement of T-cell receptor gamma chain genes in B-cell chronic lymphocytic leukemia. Leukemia Research. 13:259-266. 1989
- Characterization of Hodgkin’s Disease Derived Cell Line HDLM-2. Recent Results in Cancer Research. 117:75-82. 1989
- T-cell receptor gene rearrangement in B-Cell non-hodgkin's lymphoma: Correlation with methylation and expression. Leukemia Research. 13:473-481. 1989
- INDEPENDENT CLONAL ORIGIN OF COEXISTING CHRONIC LYMPHOCYTIC LEUKAEMIA AND MULTIPLE MYELOMA. British Journal of Haematology. 70:126-127. 1988
- Genotypes and immunophenotypes of Hodgkin's disease-derived cell lines.. Leukemia. 2:371-376. 1988
- Mixed acute leukaemias. Blood Reviews. 2:9-15. 1988
- The nature of the hodgkin cell. Blut. 56:135-137. 1988
- Rearrangement and expression of T cell antigen receptor genes in B cell chronic lymphocytic leukemia. Blood. 71:178-185. 1988
- Patterns of gene expression during plasmacytoid differentiation of chronic lymphocytic leukaemia cells. FEBS Letters. 215:127-131. 1987
- Morphine analgesia and tolerance in the tail-flick and formalin tests: Dose-response relationships. Pharmacology Biochemistry and Behavior. 17:1213-1219. 1982
-
chapter
-
conference paper
- COMPARISON OF NEXT GENERATION SEQUENCING VERSUS SINGLE ANALYTE TESTS FOR SOMATIC MUTATION DETECTION IN ACUTE MYELOID LEUKEMIA, MYELOPROLIFERATIVE NEOPLASM AND SOLID TUMORS. Clinical and Laboratory Haematology International Journal of Laboratory Hematology. 72-72. 2017
- Improved Survival from Transfusion Dependence in Lower-Risk MDS Receiving Iron Chelation, Adjusting for MDS and Patient Characteristics: An MDS-Can Analysis. Leukemia Research. S162-S163. 2017
- MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System. Leukemia Research. S131-S132. 2017
- Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. Blood. 3192-3192. 2016
- Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. Blood. 1922-1922. 2016
- A Qualitative Research Study to Understand Post-Transfusion Well-Being in Patients with Myelodysplastic Syndromes. Blood. 4446-4446. 2015
- Assessing Disease Stability of Patients with Myelodysplastic Syndrome for an Age of Blood Randomized Controlled Trial: A Chart Review. Blood. 5252-5252. 2015
- Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study. Blood. 2015
- Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL). Blood. 2015
- Multi-molecular complexes of Bcl-2 proteins regulate membrane permeabilization by Bax. Oncology Research and Treatment. 99-100. 2015
- ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL). Haematologica. 61-62. 2015
- Patient Related Factors Have an Indepedent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry. Blood. 2014
- Conformation dictates function: Membrane associated interactions of Bcl-XL with Bax, c(t) Bid and Bad. Oncology Research and Treatment. 280-280. 2014
- EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR. Haematologica. 532-532. 2014
- Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr.. Journal of Clinical Oncology. 7025-7025. 2014
- A New Form Of Therapeutic Resistance: Drug Glucuronidation Regulated By The Sonic Hedgehog Factor Gli1. Blood. 821-821. 2013
- Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up. Blood. 94-95. 2013
- Transfusion-Related Iron Overload: A Covert Risk Of Supportive Cancer Care. Blood. 3656-3656. 2013
- Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up. Journal of Clinical Oncology. 2013
- P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry. Leukemia Research. S76-S76. 2013
- Binding and Oligomerization of Bcl-2 Family Proteins on Supported Lipid Bilayers with Single Molecule Resolution. Biophysical Journal. 222a-222a. 2013
- Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up. Journal of Clinical Oncology. 2012
- A Supported Bilayer Model to Study the Effect of Membrane Composition on Bcl-2 Family Proteins. Biophysical Journal. 647a-647a. 2012
- Quantification of Protein Distribution on Liposomes using Confocal Microscopy: A Single Mobile Fluorescent Particle Detection Method. Biophysical Journal. 51a-52a. 2012
- tBid Conformational Changes at the Membrane for the Regulation of Apoptosis. Biophysical Journal. 625a-625a. 2012
- Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR, After >= 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib. Blood. 278-278. 2011
- Pre-Screening for Low Methyl Guanine Methyltransferase (MGMT) Expression Results in High Response Rates to Temozolomide (TMZ) Therapy in AML and MDS Patients. Blood. 194-195. 2011
- Evaluation of a novel class of sulfonanilides for targeted treatment of multiple myeloma: Dual-mechanism compounds inhibiting HIF1 alpha-signaling and inducing apoptosis. Onkologie. 18-18. 2011
- Abstract 660: Inhibition of centrosomal clustering suppresses tumor growth in vivo. Cancer Research. 660-660. 2011
- A Novel Class of Sulfonanilides Entering Clinical Trials for Targeted Treatment of Multiple Myeloma: Dual-Mechanism Compounds Inhibiting HIF1A-Signaling and Inducing Apoptosis. Blood. 1232-1232. 2010
- Differential Dependence On Wnt Signaling Allows Chemical Mediated Eradication of Human Acute Leukemia without Affecting Normal Blood Stem Cells. Blood. 1343-1344. 2010
- Identification of AML and MDS Patients Who Could Potentially Benefit From Temozolomide Therapy: Proportion of Patients with Low Methyl Guanine Methyltransferase (MGMT) Expression Level.. Blood. 1624-1625. 2010
- 58 Development and characterization of novel orally available Hypoxiainducible factor (HIF) signaling inhibitors as dual-mechanism cancer therapeutics. European Journal of Cancer, Supplement. 27-27. 2010
- Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS).. Journal of Clinical Oncology. 6564-6564. 2010
- Bax Pore Formation: From Activation to Oligomerization. Biophysical Journal. 464a-464a. 2010
- Effect of Different Lipid Compositions on Mitochondrial Outer Membrane Permeabilization Assisted by the Pro-Apoptotic Proteins tBID and BAX. Biophysical Journal. 465a-465a. 2010
- Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. Blood. 823-823. 2009
- Binding of the Pro-Apoptotic protein Bid to Mitochondrial Membranes is a Two Step Process. Biophysical Journal. 425a-425a. 2009
- A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood. 587-587. 2007
- A Phase I Study of Tipifarnib Combined with Conventional Induction and Consolidation Therapy for Previously Untreated Patients with Acute Myeloid Leukemia Age 60 and Over.. Blood. 899-899. 2007
- A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. Blood. 908-908. 2007
- Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥50 Years.. Blood. 1095-1095. 2007
- Characterizing Bax-tBid function at the mitochondrial membrane isolated from bak(-/-) mice. Biochemistry and Cell Biology. 1077-1078. 2006
- Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura: A case report. Transfusion. 44A-45A. 2006
- A phase II trial of oblimersen sodium (G3139) plus rituximab for treatment of patients with recurrent B-cell non-Hodgkin's lymphoma. Annals of Oncology. 68-68. 2005
- Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma.. Journal of Clinical Oncology. 587S-587S. 2005
- A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study.. Journal of Clinical Oncology. 585S-585S. 2004
- Final analysis of a randomized phase I study of the C-RAF kinase inhibitor BAY 43-9006 in patients with acute myeloid leukemia. Annals of Oncology. 154-154. 2004
- Investigation of the oligomerization of Bax at the membrane of a giant vesicle. Biophysical Journal. 462A-462A. 2004
- Ganciclovir prophylaxis is associated with delayed neutrophil engraftment in patients undergoing haploidentical transplantation.. Blood. 439B-439B. 2003
- Induction of specific immunity to B-CLL cells by in vitro stimulation using antigen pulsed autologous dendritic cells.. Blood. 439A-439A. 2003
- A randomized phase I clinical and biologic study of two schedules of the raf-kinase inhibitor BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A NCI Canada clinical trials group study. Blood. 267B-267B. 2002
- Dynamic membrane topology of Bcl-2 during apoptosis.. FASEB Journal. A522-A522. 2002
- Complete remission of acute promyelocytic leukemia with ATRA.. Blood. 222B-222B. 2001
- Cytoplasmic O-glycosylation prevents cell surface transport of E-cadherin during apoptosis. Molecular Biology of the Cell Cell Regulation. 25A-25A. 2001
- Mutants with restricted subcellular localization reveal different mechanisms and potencies for Bcl-2 and Bcl-XL mediated inhibition of doxorubicin induced apoptosis.. Clinical Cancer Research. 3719S-3720S. 2001
- Myc expression is essential for Bax conformational change and cytochrome c release in an organelle specific apoptotic pathway. FASEB Journal. A169-A169. 2001
- Assessing pore formation by Bcl-2 during apoptosis in cell lines and human leukemic cells: Cysteine 158 in the alpha 5 helical loop is in an aqueous environment.. Blood. 174B-174B. 2000
- Early loss of adhesion during apoptosis is independently regulated by BCL-2 and caspases.. Blood. 184B-184B. 1999
- Caspase dependent O-glycosylation of E-cadherin results in loss of cell adhesion during apoptosis.. Molecular Biology of the Cell Cell Regulation. 187A-187A. 1999
- Bcl-2 prevents internalization of but not caspase dependent O-glycosylation of E-cadherin. FASEB Journal. A1341-A1341. 1999
- CD34+ t(15;17) APL represents a distinct subgroup associated with CD2+, bcr3 isoform, microgranular morphology, a high white count and a poor prognosis.. Blood. 604A-604A. 1998
- Bcl-2 increases E-cadherin mediated cell adhesion prior to onset of apoptosis. Molecular Biology of the Cell Cell Regulation. 244A-244A. 1998
- The entity of CD34+ t (15; 17) acute promyelocytic leukemia. British Journal of Haematology. 100-100. 1998
- BCL-2 and Bax regulate apoptosis from different subcellular compartments.. Blood. 3598-3598. 1997
- BCL-2 and bax regulate apoptosis from different subcellular compartments. Molecular Biology of the Cell Cell Regulation. 2033-2033. 1997
- Bcl-2 mutants with restricted sub-cellular location reveal spatially distinct pathways for apoptosis in different cell types.. Blood. 2199-2199. 1996
- Bcl-2 mutants with restricted sub-cellular location reveal spatially distinct pathways for apoptosis in different cell types. FASEB Journal. 519-519. 1996
- Radiation induced apoptosis in neuroblastoma does not depend on induction of Bax. Pediatric Research. 925-925. 1996
- Bax is induced following retinoic acid treatment but cell survival depends on Bcl-2 expression. Blood. 133-133. 1995
- The effect of targeting Bcl-2 to different intracellular compartments. Blood. 2920-2920. 1995
- The role of Bcl-2 expression in mediating cisplatinum resistance.. Blood. 3113-3113. 1995
- DAY-6 BONE-MARROW (D6BM) PREDICTS FOR COMPLETE REMISSION (CR) IN ADULTS WITH ACUTE MYELOID-LEUKEMIA (AML). Blood. A303-A303. 1994
- TELOMERE LENGTH AND TELOMERASE ACTIVITY IN HEMATOLOGIC MALIGNANCIES. Blood. A38-A38. 1994
- EVIDENCE FOR PROMISCUOUS MEMBRANE ASSEMBLY OF BCL-2. Blood. A114-A114. 1993
- SUBCELLULAR-LOCALIZATION OF BCL-2 - THE HYDROPHOBIC CARBOXYL TERMINAL DOMAIN TARGETS BCL-2 TO MEMBRANES. Journal of Cellular Biochemistry. 266-266. 1993
- GENE PROBE ANALYSIS OF HODGKINS AND NON-HODGKINS LYMPHOMAS. British Journal of Haematology. 142-142. 1988
- ANALYSIS OF T-CELL ASSOCIATED REARRANGEMENT OF THE T-CELL RECEPTOR GAMMA-CHAIN GENES IN B-CLL. British Journal of Haematology. 506-506. 1988
- GENOTYPES AND IMMUNOPHENOTYPES OF HODGKINS-DISEASE DERIVED CELL-LINES. Blut. 248-248. 1987